Somalogic, Inc.

75 articles with Somalogic, Inc.

• SomaLogic Reports Fourth Quarter and Full Year 2022 Financial Results, Announces Director Appointments and Management Evolution

  3/28/2023

  SomaLogic, Inc., a leader in proteomics technology, today reported financial results for the quarter and year ended December 31, 2022 and announced a management transition, as well as the appointment of four new members to the Board of Directors.

• SomaLogic to Announce Fourth Quarter and Full Year 2022 Financial Results

  3/9/2023

  SomaLogic, Inc., a leader in proteomics technology, today announced that it will report financial results for the fourth quarter and full year 2022 after market close on Tuesday, March 28, 2023.

• SomaLogic Announces Preliminary Full Year 2022 Revenue and Provides Organizational and Strategic Updates

  1/9/2023

  SomaLogic, Inc., a leader in proteomics technology, announced that preliminary, unaudited revenue for the full year 2022 is expected to be at the high end of its guidance range of $93 to $98 million, reflecting approximately 20% year-over-year revenue growth.

• SomaLogic to Participate in the 41st Annual J.P. Morgan Healthcare Conference

  12/29/2022

  SomaLogic, Inc., a leader in proteomics technology, announced that the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference.

• FonesLife offers the 7,000-plex SomaScan® Platform as Japan’s first SomaLogic™ Certified Site

  12/19/2022

  SomaLogic, Inc., a leader in proteomic technology, announced that Tokyo-based FonesLife Corporation, will be the first SomaLogic™ Certified Site in Japan.

• SomaLogic Reports Third Quarter 2022 Financial Results

  11/14/2022

  SomaLogic (NASDAQ: SLGC), a leader in AI data-driven proteomics technology, today reported financial results for the quarter ended September 30, 2022.

• SomaLogic Teams with Molecular Genomics to Bring the 7,000-Plex SomaScan® Platform to Asia

  11/8/2022

  SomaLogic, Inc., a leader in proteomics technology, announced that Singapore-based Molecular Genomics, a Genomax Technologies company, will be the first site in Asia to offer the 7,000-plex SomaScan® Assay and provide SomaScan data to their customers.

• SomaLogic presents new research at American Heart Association Scientific Sessions that illustrates the power of proteomics in addressing cardiovascular disease

  10/31/2022

  SomaLogic, a leader in AI data-driven proteomics technology, announced findings from key studies demonstrating the broad and deep role proteomics plays in detecting cardiovascular risk, achieving optimal cardiometabolic health, and assessing the correlation of cardiovascular disease with other diseases that are among the leading causes of death around the world.

• SomaLogic to Announce Third Quarter 2022 Financial Results

  10/24/2022

  SomaLogic (NASDAQ: SLGC), a leader in AI data-driven proteomics technology, today announced that it will report financial results for the third quarter 2022 before market open on Monday, November 14, 2022.

• SomaLogic to Present at the Capital One Spatial Biology & Proteomics Summit

  9/14/2022

  SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that management will be participating in the upcoming Capital One Spatial Biology & Proteomics Summit taking place virtually on Wednesday, September 28.

• SomaLogic to Present at Morgan Stanley 20th Annual Global Healthcare Conference

  8/31/2022

  SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the company will be participating in the upcoming Morgan Stanley 20th Annual Global Healthcare Conference in New York, New York.

• SomaLogic Reports Second Quarter 2022 Financial Results

  8/15/2022

   SomaLogic, Inc., a leader in AI-data driven proteomics technology, today reported financial results for the quarter ended June 30, 2022.

• SomaLogic acquires DNA nanotechnology leader Palamedrix to develop the next-generation SomaScan® Assay

  7/26/2022

  SomaLogic (NASDAQ: SLGC), a leader in AI data-driven proteomics technology, today announced it entered into an agreement to acquire Palamedrix, Inc., an innovator in DNA nanotechnology. Palamedrix provides deep scientific and engineering expertise, miniaturization technology and enhanced ease-of-use capabilities that SomaLogic intends to leverage as it develops the next generation of the SomaScan® Assay.

• SomaLogic to Announce Second Quarter 2022 Financial Results

  7/25/2022

  SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that it will report financial results for the second quarter 2022 after market close on Monday, August 15, 2022.

• SomaLogic Announces License Agreement with OncoHost for the Development of Precision Cancer Diagnostics

  6/13/2022

  SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced it has signed a licensing agreement with OncoHost, a global leader in next-generation precision oncology for personalized cancer therapy.

• 

  Illumina and Deerfield Team Up to Utilize AI, Genomics in Drug Development

  5/5/2022

  Illumina and Deerfield Management have entered into a five-year partnership to apply a genetic-led approach to the discovery and development of novel therapies.

• SomaLogic Reports Fourth Quarter and Full Year 2021 Financial Results

  3/29/2022

  SomaLogic, Inc., a leader in AI-data driven proteomics technology, today reported financial results for the quarter and year ended December 31, 2021.

• SomaLogic to Announce Fourth Quarter and Full Year 2021 Financial Results

  3/1/2022

  SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that it will report financial results for the fourth quarter and full year 2021 after market close on Tuesday, March 29, 2022.

• SomaLogic to Participate in the Cowen 42nd Annual Health Care Conference

  2/25/2022

  SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the company will be participating in the Cowen 42nd Annual Health Care Conference.

• SomaLogic Provides 2022 Revenue Guidance in Conjunction with Analyst and Investor Meeting

  2/4/2022

  SomaLogic, Inc., a leader in AI-data driven proteomics technology, will host a virtual analyst and investor meeting today, February 4th , 2022, from 10:00 a.m. to approximately 1:00 p.m. Eastern Time.